BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-13: Form 8-K; Period of report 2018-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-09-24: Form 8-K; Period of report 2018-09-20; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2018-08-14: Form 8-K; Period of report 2018-08-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-08-13: Form 8-K; Period of report 2018-08-09; Description 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 3.03.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-13 | 8-K | 2018-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2018, we issued a press release announcing our financial results for the three and nine months ended September 30, 2018. | bioc-8k_20181113.htm |
| 2018-09-24 | 8-K | 2018-09-20 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 Please see the disclosure regarding the Purchase Warrants and the Purchase Warrant Shares set forth under Item 1.01, which is incorporated by reference into this Item 3.02. 8.01 On September 21, 2018, the Company issued a press release announcing the offering described in Item 1.01 above, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | bioc-8k_20180920.htm |
| 2018-08-14 | 8-K | 2018-08-14 | 2.02 Results of Operations and Financial Condition | 2.02 On August 14, 2018, we issued a press release announcing our financial results for the three and six-months ended June 30, 2018. | bioc-8k_20180814.htm |
| 2018-08-13 | 8-K | 2018-08-09 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 3.03 To the extent required by Item 3.03 of Form 8-K, the information regarding the Certificate of Designation (defined below) contained in Item 5.03 of this report is incorporated by reference herein. 5.03 On August 9, 2018, Biocept, Inc. (the “Company”) filed a Certificate of Designation of Preference, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Delaware Secretary of State creating a new series of its authorized preferred stock, par value $0.0001 per share, designated as the “Series A Convertible Preferred Stock” (the “Series A Preferred Stock”). 8.01 On August 13, 2018, the Company completed its previously announced rights offering pursuant to its effective registration statement on Form S-1, as amended (Registration Statement No. 333-225147), previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”), and a prospectus filed with the SEC (the “Rights Offering”). | bioc-8k_20180810.htm |
| 2018-07-25 | 8-K | 2018-07-24 | 8.01 Other Events | 8.01 On January 22, 2018, Biocept, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had failed to comply with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). | bioc-8k_20180725.htm |
| 2018-07-06 | 8-K | 2018-07-06 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 3.03 See Item 5.03 of this report which is incorporated into this Item 3.03 by this reference. 5.03 As discussed below in Item 5.07, the stockholders of Biocept, Inc. (the “Company”) approved a proposal to amend the Company’s Certificate of Amendment of Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1:20 to 1:30, such ratio to be determined in the discretion of the Company’s board of directors. 5.07 On June 28, 2018, the Company held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders voted on and approved Proposals 1, 2, 3 and 5, as further described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 3, 2018. | bioc-8k_20180706.htm |
| 2018-07-03 | 8-K | 2018-06-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As discussed below in Item 5.07, Biocept, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved amendments to the Company’s Amended and Restated 2013 Equity Incentive Plan, as amended (the “2013 Plan”), to, among other things, increase the number of shares of the Company’s common stock available for issuance under the 2013 Plan by 4,400,000. 5.07 On June 28, 2018, the Company held the Annual Meeting. | bioc-8k_20180628.htm |
| 2018-05-15 | 8-K | 2018-05-15 | 2.02 Results of Operations and Financial Condition | 2.02 On May 15, 2018, we issued a press release announcing our financial results for the three months ended March 31, 2018. | bioc-8k_20180515.htm |
| 2018-04-06 | 8-K | 2018-04-03 | 5.08 Shareholder Director Nominations | bioc-8k_20180403.htm | |
| 2018-03-28 | 8-K | 2018-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2018, we issued a press release announcing our financial results for the three months and year-ended December 31, 2017. | bioc-8k_20180328.htm |
| 2018-02-12 | 8-K | 2018-02-06 | 5.08 Shareholder Director Nominations | bioc-8k_20180206.htm | |
| 2018-01-30 | 8-K | 2018-01-30 | 8.01 Other Events | bioc-8k_20180130.htm | |
| 2018-01-23 | 8-K | 2018-01-22 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | bioc-8k_20180122.htm |